Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide

Blood

Volumn 98, Issue 2, 2001, Pages 266-271

  Westervelt, Peter ^a,b,c,d   Brown, Randy A ^a,b,c,d   Adkins, Douglas R ^a,b,c,d   Khoury, Hanna ^a,b,c,d   Curtin, Peter ^a,b,c,d   Hurd, David ^a,b,c,d   Luger, Selina M ^a,b,c,d   Ma, Margaret K ^a,b,c,d   Ley, Timothy J ^a,b,c,d   DiPersio, John F ^a,b,c,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 5081; ARSENIC TRIOXIDE;

ADULT; AGED; ARTICLE; BONE PAIN; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FATALITY; DRUG SAFETY; DYSPNEA; EDEMA; FEMALE; FEVER; HEARING LOSS; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; MALE; MYALGIA; PANCREATITIS; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT INTERVAL; SUDDEN DEATH; TINNITUS;

EID: 0035880237     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.2.266     Document Type: Article

References (19)

1. Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all trans-retinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. European APL 91 Group. Blood. 1993;82:3241-3249.
2. Tallman MS, Andersen JW, Schiffer CA, et al. All trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
3. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: the European APL Group. Blood. 1999;94:1192-1200.
4. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood. 1999;93:4131-4143.
5. Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integr Traditional Western Med. 1992;12:170-171.
6. Huang SL, Guo AX, Xiang Y, Wang XB, Ling HJ, Fu L. Clinical study on the treatment of APL mainly with composite Indigo Naturalis tablets. Chin J Hematol. 1995;16:26.
7. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360.
8. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1999;339:1341-1348.
9. Soignet, S, Frankel, S, Tallman, M, et al. U.S. multicenter trial of arsenic trioxide in acute promyelocytic leukemia [abstract]. Blood. 1999;94(suppl 1):698.
10. Densmore, J, Hess C, Ross M. Sensorimotor polyneuropathy following arsenic trioxide therapy for relapsed acute promyelocytic leukemia [abstract]. Blood. 1999;94(suppl 1):228.
11. Westervelt P, Pollock J, Ley TJ, DiPersio JF. Response and toxicity associated with dose escalation of arsenic trioxide in the treatment of acute promyelocytic leukemia [abstract]. Blood. 1997;90(suppl 1):249.
12. Huang SY, Chang CS, Tang JL, et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol. 1998;103:1092-1095.
13. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979:9:115-134.
14. St Petery J, Gross C, Victorica BE. Ventricular fibrillation caused by arsenic poisoning. Am J Dis Child. 1970;120:367-371.
15. Goldsmith S, From AH. Arsenic-induced atypical ventricular tachycardia. N Engl J Med. 1980;303:1096-1098.
16. Beckman KJ, Bauman JL, Pimental PA, Garrard C, Hariman RJ. Arsenic-induced torsade de pointes. Crit Care Med, 1991;19:290-292.
17. Huang CH, Chen WJ, Wu CC, Chen YC, Lee YT. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemia patient. Pacing Clin Electrophysiol. 2000;22:965-967.
18. Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood. 2001;97:1514-1516.
19. Vahter M. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol Lett. 2000;112-113:209-217.